17:25:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-27 X-dag ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 Årsstämma 2024
2024-06-24 Kvartalsrapport 2024-Q1
2024-03-27 Extra Bolagsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 X-dag ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 X-dag ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 X-dag ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 X-dag ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50


ListaEuronext Growth Oslo
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2024-03-27 09:40:01
Not for release, publication or distribution, in whole or in part directly or
indirectly, in Australia, Canada, Japan or the United States (or any other
jurisdiction in which the release, publication or distribution would be
unlawful). This announcement does not constitute an offer of any of the
securities described herein.

Oslo, 27 March 2024: Reference is made to the stock exchange release from Softox
Solutions AS (the "Company") on March 13th 2024 regarding summons for
extraordinary general meeting with agenda inter alia contemplated conversion of
debt to equity, private placement and repair issue (the "EGM").

Private Placement

The Company hereby announces that is has raised NOK 22,330,571 in gross proceeds
in the contemplated private placement ("Private Placement"), divided by NOK
14.005.371 by way of conversion of supplier debt and NOK 8.325.200 in cash,
through the allocation of 111,652,854 new shares, at a subscription price per
share in the Private Placement of NOK 0,2 per share (the Offer Price"). The
Offer Price was set through a bookbuilding process conducted by the Company's
manager SpareBank 1 Markets.

The consummation of the Private Placement by the issuance of the new shares will
be subject to approval by the EGM, scheduled to be held tomorrow 27 March 2024
at 10 a.m. CET.

Settlement of the new shares in the Private Placement is expected to take place
on or about 2nd April 2024, subject to registration of the share capital
increase in the Company pertaining to the issuance of the New Shares by the
Norwegian Register of Business Enterprises (the "NRBE"), on a
delivery-versus-payment ("DVP") basis.

The new shares are expected to be tradable from on or about 8th April 2024, but
not before registration of the share capital increase in the Company pertaining
to the issuance of the new shares by the NRBE.

The net cash proceeds from the Private Placement will be used to secure the
Company's data and patent portfolio, as well as funding operations at a minimum
level over the next 3-6 months.

The aforementioned result of the Private Placement and Offer Price will result
in adjustments being made in the final resolutions to be made by the EGM, inter
alia the adjustment of the final number of shares to be issued and the Offer

Debt Conversion

The Company has also agreed with creditors that shall convert their loans of
approximately NOK 76.208.596 into new shares in the Company (the "Debt
Conversion") that the conversion shall be based on the same principles as in the
Private Placement. Consequently, the subscribers in the Debt Conversion will
convert NOK 76.208.596 and be allocated 381,042,981 new shares at a subscription
price per share equal to the Offer Price.

The conditions and principles described above for completion and delivery of new
shares in the Private Placement also applies for the Debt Conversion.

New share capital

Following registration of the new shares pertaining to the Private Placement and
the Debt Conversion, the Company will have a share capital of NOK 10.068.474
divided into 503.423.706 shares, each with a par value of NOK 0.02.

Equal treatment considerations

The Private Placement and the Debt Conversion represents a deviation from the
shareholders' pre-emptive right to subscribe for and be allocated the Offer
Shares. The Board has considered the Private Placement and the Debt Conversion
in light of the equal treatment obligations under the Norwegian Securities
Trading Act and the principles set out in Oslo Børs' Circular no. 2/2014 and is
of the opinion that the waiver of the preferential rights inherent in a private
placement is considered necessary in the interest of time and successful
completion in order to secure funding of and the viability of the Company.
Further, the Private Placement was launched after a market sounding process with
a number of investors (including both new investors and existing shareholders)
to reduce the transaction risk, and the transaction has been marketed through a
process to secure a market-based offer price. In addition, the Private Placement
and the Debt Conversion is conditioned upon the EGM resolution at which the
Company's shareholders will be given an opportunity to express their opinion and
vote over the related share capital increases. Taking into consideration the
time, costs and expected terms of alternative methods of securing the necessary
funding, as well as the proposed Subsequent Offering (as described below), the
Board has concluded that the completion of the Private Placement and the Debt
Conversion, including the waiver of the preferential rights inherent to the
Private Placement, is in the common interest of the shareholders of the Company.

Subsequent Offering

Subject to completion of the Private Placement and the Debt Conversion and
certain other conditions, the Company will carry out a subsequent offering of up
to 125,000,000 new shares which, if applicable and subject to applicable
securities laws, will be directed towards existing shareholders in the Company
as of as of March 27 2024, as registered in the Company's shareholder register
at Euronext Securities Oslo (VPS) on 3 April 2024, and who (i) were not included
in the pre-sounding phase of the Private Placement, (ii) were not allocated
offer shares in the Private Placement, and (iii) are not resident in a
jurisdiction where such an offer would be illegal or would (in jurisdictions
other than Norway) require a prospectus, filing, registration, or similar action
(the "Subsequent Offering"). The subscription price in the Subsequent Offering
will be equal to the Offer Price.

The Subsequent Offering will be subject to (i) a resolution by the EGM tomorrow
27 March 2024 approving the amended proposal for Subsequent Offering, (ii) the
prevailing market price of the Company's shares and (iii) registration of a
national prospectus.

Further information about the Subsequent Offering will be given in a future
stock exchange notice. The Board reserves the right not to carry out the
Subsequent Offering in the event

that the Company's shares trade at or below the subscription price in the
Subsequent Offering (i.e. the Offer Price) at meaningful volumes.

For any questions or interview requests, please contact:
Geir Almås, Chair of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Geir Almås: (+47) 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com